Article
Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy.
Epilepsia - 1 Jul 2023
Knight Devon, Mahida Sonal, Kelly Mckenna, Poduri Annapurna, Olson Heather E
Abstract excerpt
Genetic variants in KCNQ2 are associated with a range of epilepsies, from self- limited (familial) neonatal-infantile epilepsy to developmental and epileptic encephalopathy (DEE). We retrospectively reviewed clinical data from eight patients with KCNQ2-related DEE who were treated with ezogabine. Treatment was initiated at a median age of 8 months (range, 7 weeks to 2.5 years) and continued for a median of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
